NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis $1.37 -0.02 (-1.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.35▼$1.3750-Day Range$1.24▼$1.5652-Week Range$1.15▼$2.98Volume3,416 shsAverage Volume45,839 shsMarket Capitalization$4.43 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Artelo Biosciences alerts: Email Address Artelo Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside265.0% Upside$5.00 Price TargetShort InterestHealthy0.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.09) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.22 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArtelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Artelo Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.04% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently decreased by 91.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARTL. Previous Next 3.3 News and Social Media Coverage News SentimentArtelo Biosciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Artelo Biosciences this week, compared to 0 articles on an average week.Search Interest4 people have searched for ARTL on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.90% of the stock of Artelo Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.87% of the stock of Artelo Biosciences is held by institutions.Read more about Artelo Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Artelo Biosciences are expected to grow in the coming year, from ($2.09) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtelo Biosciences has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Artelo Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About Artelo Biosciences Stock (NASDAQ:ARTL)Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Read More ARTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTL Stock News HeadlinesJuly 22, 2024 | americanbankingnews.comComparing Provectus Biopharmaceuticals (OTCMKTS:PVCT) and Artelo Biosciences (NASDAQ:ARTL)July 15, 2024 | globenewswire.comArtelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 InhibitorJuly 26, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.July 3, 2024 | globenewswire.comArtelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society SymposiumJune 4, 2024 | globenewswire.comArtelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain SocietyMay 29, 2024 | globenewswire.comArtelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24May 13, 2024 | finance.yahoo.comArtelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | globenewswire.comArtelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateJuly 26, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.May 10, 2024 | globenewswire.comArtelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14thApril 23, 2024 | globenewswire.comArtelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyApril 22, 2024 | globenewswire.comArtelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeMarch 25, 2024 | benzinga.comRecap: Artelo Biosciences Q4 EarningsMarch 25, 2024 | msn.comArtelo Biosciences GAAP EPS of -$3.14 misses by $0.58March 25, 2024 | globenewswire.comArtelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMarch 12, 2024 | globenewswire.comArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation ChallengeFebruary 15, 2024 | finanznachrichten.deArtelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thJanuary 8, 2024 | finance.yahoo.comArtelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12See More Headlines Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARTL CUSIPN/A CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+265.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.82% Return on Assets-69.00% Debt Debt-to-Equity RatioN/A Current Ratio11.36 Quick Ratio11.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.12 per share Price / Book0.33Miscellaneous Outstanding Shares3,230,000Free Float3,005,000Market Cap$4.43 million OptionableNot Optionable Beta1.43 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gregory D. Gorgas M.B.A. (Age 61)President, CEO, CFO, Treasurer, Secretary & Director Comp: $742.45kDr. Andrew Yates Ph.D.Senior VP & Chief Scientific OfficerDr. Steven D. Reich (Age 78)Chief Medical Officer Mr. Jason H. Baybutt (Age 52)Senior Vice President of Finance Key CompetitorsAptorum GroupNASDAQ:APMVBI VaccinesNASDAQ:VBIVPharmaCyte BiotechNASDAQ:PMCBUnicycive TherapeuticsNASDAQ:UNCYKiora PharmaceuticalsNASDAQ:KPRXView All Competitors ARTL Stock Analysis - Frequently Asked Questions How have ARTL shares performed this year? Artelo Biosciences' stock was trading at $1.40 at the beginning of 2024. Since then, ARTL shares have decreased by 2.1% and is now trading at $1.37. View the best growth stocks for 2024 here. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.27. When did Artelo Biosciences' stock split? Artelo Biosciences shares reverse split on the morning of Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN) and OPKO Health (OPK). This page (NASDAQ:ARTL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
